BOCA RATON, Fla. - INmune Bio Inc. (NASDAQ:INMB), a clinical-stage biotech company, recently announced key findings from a study published in the Journal of Immunotherapy of Cancer.
The research, co-authored by the company's Chief Scientific Officer, Dr. Mark Lowdell, revealed that memory-like natural killer (mlNK) cells, which can be generated by INKmuneTM priming, exhibit increased effectiveness in destroying multiple types of tumors.
This study is particularly significant as it demonstrates for the first time that mlNK cells can be generated in vivo, meaning within a living organism, which contrasts with the traditional cytokine cocktail used in vitro, or outside a living organism. The ability to produce these mlNK cells in patients is a crucial step in validating INmune Bio's therapeutic approach.
INKmuneTM is designed to convert a cancer patient's resting NK cells into mlNK cells capable of attacking tumors. The treatment has shown that these primed cells can survive in patients for over 100 days and are functional even in the low-oxygen environment of tumors due to their upregulated nutrient receptors and mitochondrial survival proteins.
The research also highlighted the enhanced metabolic function of NK cells primed by INKmuneTM, which is key as NK cell dysfunction within the tumor microenvironment is often linked to impaired metabolism. Overcoming these metabolic barriers could lead to more effective NK cell responses against tumors.
These findings are timely as INmune Bio is currently conducting a Phase I/II trial of INKmuneTM for metastatic castration-resistant prostate cancer, with preliminary results expected later in the year.
INKmuneTM has been described as a tumor-agnostic treatment, potentially applicable to a wide range of NK-resistant tumors, including leukemia, lymphoma, myeloma, and various solid tumors. The drug is administered through a simple intravenous infusion and does not require pre-medication or additional cytokine therapy.
INmune Bio's research represents a commercial and academic collaboration spanning several years, culminating in the publication of their work in a peer-reviewed scientific journal.
The company continues to focus on harnessing the innate immune system to fight disease, with two product platforms currently in clinical trials targeting hematologic and solid tumor malignancies, as well as chronic inflammation.
This article is based on a press release statement from INmune Bio Inc. detailing their recent research publication.
In other recent news, INmune Bio, a clinical-stage biotechnology company, has shown optimism regarding its ongoing clinical trials for Alzheimer's disease and prostate cancer, as shared in its first-quarter 2024 earnings call.
The company reported a net loss of $11 million for the quarter, but recent fundraising efforts that raised $14.5 million in gross proceeds have bolstered its financial position.
This development comes alongside the announcement that INmune Bio is set to join the Russell 3000 Index starting from July, reflecting the company's market presence and potential for increased visibility within the investment community.
The company's CEO, Dr. RJ Tesi, expressed enthusiasm about the potential for accelerated approval for XPro, its Alzheimer's therapy, and the progress of the INKmune program for treating prostate cancer.
INmune Bio is also on track with its Phase II Alzheimer's trial, AD02, expecting to meet target enrollment by mid-2024. The INKmune program for prostate cancer is progressing well, with the Phase I/II trial expected to enroll 30 patients.
These are recent developments that highlight the company's ongoing efforts in the biotechnology sector. The company's inclusion in the Russell 3000 Index and their progress in clinical trials underscore their commitment to developing treatments for diseases such as Alzheimer's and prostate cancer.
InvestingPro Insights
In the wake of INmune Bio Inc.'s (NASDAQ:INMB) promising research on memory-like natural killer (mlNK) cells, the financial metrics show a company experiencing significant volatility. According to InvestingPro, INmune Bio holds more cash than debt, which could provide some financial flexibility as they continue their clinical trials and research endeavors. However, the stock has recently taken a substantial hit, with a one-week price total return showing a decrease of 13.39%. This volatility is also reflected in the stock's price movements, which have been quite erratic.
The InvestingPro data highlights a challenging financial outlook, with a market capitalization of $168.94 million and a negative P/E ratio of -4.9 for the last twelve months as of Q1 2024. This suggests that investors are wary of the company's profitability in the near term. Analysts do not anticipate INmune Bio will be profitable this year, and net income is expected to drop. The revenue decline is stark, with a decrease of 47.39% over the last twelve months as of Q1 2024, and an even sharper quarterly revenue decline of 63.16% for Q1 2024.
Despite these financial headwinds, INmune Bio's research offers potential for future breakthroughs in cancer treatment. For investors interested in the biotech sector, the company's progress in clinical trials and subsequent market performance should be monitored closely. For those seeking additional insights, InvestingPro offers a total of 11 InvestingPro Tips on INMB, which can be accessed with the promo code PRONEWS24 for up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.